October 2017

Important New Products

• Hexaxim (DTPa-hepB-IPV-Hib vaccine) combines diphtheria toxoid, tetanus toxoid, acellular ...(more)
• NovoThirteen (catridecacog (rys)) is a recombinant human coagulation factor XIII A-subunit. ...(more)
• Rexulti (brexpiprazole) is a novel atypical antipsychotic agent with pharmacological ...(more)
• Somavert (pegvisomant (rbe)) is an analogue of human growth hormone that has been ...(more)
• Tecentriq (atezolizumab (rch)) is a humanised monoclonal antibody that directly binds to ...(more)

New Indications

• Lucentis (ranibizumab) is now indicated in adults for the treatment of visual impairment due ...(more)

New Contraindications

• Colifoam Rectal Foam (hydrocortisone acetate) is now contraindicated with tuberculous or ...(more)
• Evotaz (atazanavir sulfate/cobicistat) and Reyataz (atazanavir sulfate) should not be used ...(more)
• Merieux Inactivated Rabies Vaccine (inactivated rabies vaccine) pre-exposure vaccination ...(more)
• Sporanox Capsules (itraconazole) and Sporanox Oral Solution (itraconazole) are now ...(more)
• Tarka (trandolapril/verapamil) is now contraindicated in combination with neprilysin ...(more)

IMgateway Drug Herb and Food and Supplement Interaction Database

Recent updates to the Interactions Database

The Interactions Database continues to expand, now including over 950 interactions . Recent additions include comprehensive advice on interactions between commonly consumed traditional medicines, supplements with a range of conventional medicines. New information includes interactions in the following areas: ...(more)

Active Ingredient Naming Changes

In this release, MIMS Australia will be including the following INNs (International Non-proprietary Names) as well as Australian Approved Names (AANs) as part of our push to support the Therapeutic Goods Administration (TGA) active ingredient name changes project.  

MIMS will begin referring to these ingredients by their new names, however, users may continue to search by the old AANs if preferred. ...(more)